Endocrine Abstracts

Metabolic syndrome (MetS) is known to be associated with low levels of vitamin D. The association of vitamin D in postmenopausal women with MetS and osteoporosis has not been investigated. The aim of our investigation was to assess presence of MetS in postmenopausal women treated for osteoporosis.

Metods: Fifty-nive women treated with weekly alendronate, vitamin D (Fosavance 5600, MSD) and calcium for 1 year were evaluated. The following parameters were assessed: DEXA at the level of lumbar spine and hip, parathyroid hormone levels (PTH), 25 hydroxycholecalciferol (25OHD3), lipids and glucose levels, blood pressure, waist circumfrence and BMI.

Results: Mean age of subjects was 65.6±8.1 years, indicating late start of osteoporosis treatment. After 1 year of therapy, osteoporosis was still present in 37, osteopenia in 17, while five women attained normal bone mineral density. Metabolic syndrome was found in 38 women. The mean concentration of 25OHD3 in women with metabolic syndrome was 59.1±23.3 nmol/l, while it was 114.25±35.6 nmol/l (P<0.05) in those with no MetS. Levels of PTH did not differ between the groups. Metabolic syndrome was present in 45.2% of women with osteopenia, 54.8% of those with osteoporosis and in three women with normal bone mineral density, after 1 year of treatment of osteoporosis. Metabolic syndrome was not present in 71.4% of women with osteoporosis, 28.6% of them with osteopenia and in two women with normal bone mineral density while of weekly alendronate therapy.

Conclusion: Low levels of vitamin D in postmenopausal women with MetS may compromise treatment of osteoporosis. Evaluation of vitamin D levels prior to treatment and it’s adequate supplementation in women with MetS, may improve outcome of treatment with alendronate.

DOI: 10.1530/endoabs.31.P20